A Sickle CEll Disease ComplicatioN Trial

A Phase 3, Prospective, Randomized, Double-Blind, Placebo Controlled, Multi-center Study of SC411 for Sickle Cell Disease

Status

UNKNOWN

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02604368

Acronym

ASCENT

Enrollment

210

Registered

2015-11-13

Start date

2019-03-31

Completion date

2020-12-31

Last updated

2019-02-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sickle Cell Disease

Keywords

hemoglobin SS, hemoglobin SC, hemoglobin S/β°-thalassemia

Brief summary

The objective of this study is to assess the efficacy of SC411 in reducing the number of sickle cell crisis (SCC) events in sickle cell disease (SCD) subjects receiving SC411 compared to those subjects receiving placebo.

Detailed description

This Phase 3, prospective, randomized, double-blinded, placebo-controlled, multi-center study will enroll approximately 210 subjects at up to 70 sites in the United States. Participation will consist of a Screening Period, followed by a minimum 12-month Treatment Period. SC411 is administered orally as a soft gel mini capsule. This study will enroll subjects aged ≥5 to ≤17 years who have a diagnosis of SCD that includes the phenotypes hemoglobin SS homozygous (HbSS), hemoglobin SC (HbSC), and hemoglobin S/β°-thalassemia (HbS/ β°-thalassemia); and have had at least 2 but no more than 10 documented SCC events (as defined above) within 12 months prior to the Screening Visit.

Interventions

DRUGSC411

Soft gelatin capsule

DRUGPlacebo

Soft gelatin capsule

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender

ALL

Age

5 Years to 17 Years

Healthy volunteers

Inclusion criteria

Patients who meet all of the following criteria will be eligible to participate in the study: 1. 1\. Aged ≥ 5 years and ≤ 17 years at screening; 2. Has been diagnosed with SCD (that includes the genotypes HbSS, HbSC, and HbS/β°-thalassemia, documented by hemoglobin HPLC or electrophoresis); 3. Has had between ≥ 2 to ≤10 episodes of acute SCC (as defined above) within 12 months of the Screening Visit. At least one crisis must have been managed in a hospital, clinic, or emergency room. For at least 2 of the episodes, the site must obtain the documentation created in a medical record at the time of the event. 4. Must not be receiving HU or L-Glutamine, or if receiving HU and/or L-Glutamine must be at a stable weight-based treatment regimen (mg/kg), for at least 3 months prior to the Screening Visit with the intent to continue at a weight-based dose level at the discretion of the treating physician for the duration of the study, other than for safety reasons. If taking HU and/or L-glutamine, subjects must have had at least one SCC event (as previously defined) while on HU and/or L-Glutamine. 5. Has a parent or guardian who is able to give written informed consent, and the potential pediatric subject must be able to provide assent in a manner approved by the Institutional Review Board (IRB) and comply with the requirements of the study; and 6. If post pubertal in the opinion of the Investigator, must agree to use a reliable method of birth control (e.g., barrier, birth control pills, abstinence) during the study and for 1 month following the last dose of study drug.

Exclusion criteria

Patients who meet any of the following criteria will be excluded from participation in the study: 1. A known allergy or hypersensitivity to fish or shellfish; 2. A known allergy or hypersensitivity to soy; 3. Inability to swallow capsules; 4. History of treatment with SC411; 5. Confirmed diagnosis of chronic pain or chronic opioid use: Defined as pain experienced ≥3 days per week over a 6-month period or daily opioid use for pain management; 6. Active infection with Human Immunodeficiency Virus (HIV), Hepatitis B, or Hepatitis C; 7. Prothrombin time \> 1.5 x ULN at screening; 8. Required regular anticoagulation or chronic aspirin therapy; 9. Moderate thrombocytopenia, defined as platelets \< 80,000/µL at screening; 10. History of stroke or Moyamoya syndrome; 11. Abnormal results on most recent transcranial Doppler (TCD) evaluation; 12. Received blood transfusion or blood products in the 2 months prior to the Screening Visit or on chronic blood transfusion; 13. Chronic renal insufficiency, defined as a eGFR \< 30ml/min at screening as estimated by the Schwartz equation (Appendix H), or requiring peritoneal or hemodialysis; 14. Abnormal liver function tests (ALT \> 3.0 x ULN) at screening; 15. Received any organ transplant; 16. Has a recent acute illness or other concomitant chronic medical or psychiatric condition that in the opinion of the Investigator would compromise participation in the study, prevent adherence to the protocol or confound the evaluation of the study outcome; 17. Is pregnant or lactating, or has the intention of becoming pregnant during the study (if a female of child-bearing potential or partner of a female of child-bearing potential and sexually active and not willing to use an effective means of birth control); 18. Is currently taking or has been treated with any form of omega-3 fatty acid or fish oil supplement within 30 days of the Screening Visit, or intends to do so during the course of the study; 19. Has been treated with any investigational product within 30 days of the Screening Visit or intends to receive an investigational product during the course of this study; and 20. There are factors that, in the judgment of the Investigator, would make it difficult for the patient to comply with the requirements of the study

Design outcomes

Primary

Measure	Time frame	Description
Assessment of the efficacy of SC411 in reducing the number of sickle cell crisis (SCC) events in subjects compared to placebo will be measured by counting the number of sickle cell crises that occur after randomization.	52 weeks	Assessment of the efficacy of SC411 in reducing the number of sickle cell crisis (SCC) events in subjects compared to placebo will be measured by counting the number of sickle cell crises that occur after randomization. The primary objective of this study is to assess the efficacy of orally administered SC411 in reducing the number of sickle cell crisis (SCC) events in sickle cell disease (SCD) subjects compared to placebo. A SCC event will be defined as either an acute painful crisis or an acute chest syndrome.

Secondary

Measure	Time frame	Description
Evaluation of the effect of SC411 compared to placebo by measuring the time until the patient's first sickle cell event.	52 weeks	Evaluation of days to the first event from randomization for each patient.
Evaluation of the effect of SC411 compared to placebo by measuring the the number of visits to a medical facility (hospital, clinic, or emergency room) for SCC event or complications of SCD.	52 weeks	Evaluation of the effect of SC411 compared to placebo by measuring the the number of visits to a medical facility (hospital, clinic, or emergency room) for SCC event or complications of SCD.
Evaluation of the effect of SC411 compared to placebo by measuring the number of days with electronic diary (eDiary)-recorded opioid or non opioid analgesic use at home to manage sickle cell pain.	52 weeks	To evaluate the effect of SC411 compared to placebo by measuring the number of days with electronic diary (eDiary)-recorded opioid or non opioid analgesic use at home to manage sickle cell pain.
Evaluation of the effect of SC411 compared to placebo by measuring the number of crisis-free days.	52 weeks	To evaluate the effect of SC411 compared to placebo by measuring the number of crisis-free days. A crisis-free day is defined as any day with a zero entry on the eDiary pain intensity scale.

Other

Contacts

Primary ContactUche Sampson, MD

usampson@micellebio.com615-678-2336

Backup ContactGeorge Steinfels, PhD

gsteinfels@micellebio.com301-742-5656

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026